Assenagon Asset Management S.A. Jounce Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 12, 2023	SELL	$0.64 - $1.99 $177,736 - $552,648	-277,713 Reduced 34.7%	522,578 $580,000
Q3 2022 Oct 27, 2022	SELL	$2.73 - $4.92 $1.56 Million - $2.81 Million	-571,100 Reduced 41.64%	800,291 $1.87 Million
Q2 2022 Jul 27, 2022	SELL	$2.8 - $7.67 $260,234 - $712,857	-92,941 Reduced 6.35%	1,371,391 $4.16 Million
Q1 2022 Apr 25, 2022	BUY	$6.01 - $8.54 $7.52 Million - $10.7 Million	1,251,313 Added 587.42%	1,464,332 $9.94 Million
Q4 2021 Feb 01, 2022	SELL	$7.11 - $9.64 $170 - $231	-24 Reduced 0.01%	213,019 $1.78 Million
Q3 2021 Oct 19, 2021	SELL	$5.04 - $8.73 $2.37 Million - $4.1 Million	-469,827 Reduced 68.8%	213,043 $1.58 Million
Q2 2021 Jul 15, 2021	BUY	$6.58 - $10.66 $4.49 Million - $7.28 Million	682,870 New	682,870 $4.64 Million
Q3 2019 Oct 16, 2019	SELL	$3.33 - $4.93 $689,976 - $1.02 Million	-207,200 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$4.3 - $6.73 $304,870 - $477,157	-70,900 Reduced 25.49%	207,200 $1.03 Million
Q1 2019 Apr 26, 2019	BUY	$3.43 - $6.87 $789,273 - $1.58 Million	230,109 Added 479.48%	278,100 $1.72 Million
Q4 2018 Jan 23, 2019	BUY	$2.69 - $6.71 $129,095 - $322,019	47,991 New	47,991 $162,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.